Biogen Inc. is a global biotechnology company focused on discovering, developing, and manufacturing therapies for neurological and neurodegenerative diseases, rare genetic disorders, and immunology. Founded in 1978 and combined with IDEC Pharmaceuticals in 2003, the company is headquartered in Cambridge, Massachusetts, and is publicly traded on Nasdaq (BIIB).
Biogen’s portfolio includes multiple sclerosis treatments (such as Avonex, Tysabri, Tecfidera, Plegridy, and Vumerity), Spinraza for spinal muscular atrophy, and Skyclarys for Friedreich’s ataxia. It co-develops and co-commercializes the Alzheimer’s disease therapy Leqembi with Eisai. The company also markets biosimilars in Europe (including Benepali, Imraldi, and Flixabi). Biogen operates large-scale biologics development and manufacturing facilities in the U.S. and Europe and maintains a broad network of research collaborations across industry and academia.